| scholarly article | Q13442814 |
| P50 | author | Jean-Francois Rolland | Q58227354 |
| Annamaria De Luca | Q42518905 | ||
| P2093 | author name string | S Simonetti | |
| B Nico | |||
| V Longo | |||
| A Cozzoli | |||
| R F Capogrosso | |||
| V T Sblendorio | |||
| P2860 | cites work | Protective effect of taurine on myocardial antioxidant status in isoprenaline-induced myocardial infarction in rats | Q46783218 |
| Anti-TNFalpha (Remicade) therapy protects dystrophic skeletal muscle from necrosis. | Q47850050 | ||
| Streptomycin reduces stretch-induced membrane permeability in muscles from mdx mice. | Q50475477 | ||
| Overactivity of exercise-sensitive cation channels and their impaired modulation by IGF-1 in mdx native muscle fibers: beneficial effect of pentoxifylline. | Q50719694 | ||
| Role of tumour necrosis factor alpha, but not of cyclo-oxygenase-2-derived eicosanoids, on functional and morphological indices of dystrophic progression in mdx mice: a pharmacological approach. | Q51007790 | ||
| Nuclear magnetic resonance spectroscopy study of muscle growth, mdx dystrophy and glucocorticoid treatments: correlation with repair. | Q52187221 | ||
| Microarray analysis of mdx mice expressing high levels of utrophin: therapeutic implications for dystrophin deficiency. | Q53546445 | ||
| Automated drug screening with contractile muscle tissue engineered from dystrophic myoblasts | Q24629251 | ||
| Effect of taurine on sarcoplasmic reticulum function and force in skinned fast-twitch skeletal muscle fibres of the rat | Q28344429 | ||
| Alteration of excitation-contraction coupling mechanism in extensor digitorum longus muscle fibres of dystrophic mdx mouse and potential efficacy of taurine | Q28354192 | ||
| IRES-mediated translation of utrophin A is enhanced by glucocorticoid treatment in skeletal muscle cells | Q28472887 | ||
| How calcium influx through calcium leak channels is responsible for the elevated levels of calcium-dependent proteolysis in dystrophic myotubes | Q34204770 | ||
| Molecular pathophysiology and targeted therapeutics for muscular dystrophy | Q34360418 | ||
| Risk assessment for the amino acids taurine, L-glutamine and L-arginine | Q34759622 | ||
| Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations | Q34926082 | ||
| A multidisciplinary evaluation of the effectiveness of cyclosporine a in dystrophic mdx mice. | Q35083651 | ||
| Lipid peroxidation inhibition blunts nuclear factor-kappaB activation, reduces skeletal muscle degeneration, and enhances muscle function in mdx mice. | Q35087995 | ||
| Taurine: new implications for an old amino acid | Q35557375 | ||
| Taurine and skeletal muscle disorders | Q35678828 | ||
| A novel mechanism of myocyte degeneration involving the Ca2+-permeable growth factor-regulated channel | Q36323554 | ||
| Towards developing standard operating procedures for pre-clinical testing in the mdx mouse model of Duchenne muscular dystrophy | Q36841572 | ||
| Emerging strategies for cell and gene therapy of the muscular dystrophies | Q36960845 | ||
| New therapies for Duchenne muscular dystrophy: challenges, prospects and clinical trials. | Q36993575 | ||
| Shifts in macrophage phenotypes and macrophage competition for arginine metabolism affect the severity of muscle pathology in muscular dystrophy | Q37090043 | ||
| Checking your SOCCs and feet: the molecular mechanisms of Ca2+ entry in skeletal muscle | Q37305499 | ||
| Developing standard procedures for murine and canine efficacy studies of DMD therapeutics: report of two expert workshops on "Pre-clinical testing for Duchenne dystrophy": Washington DC, October 27th-28th 2007 and Zürich, June 30th-July 1st 2008. | Q37396962 | ||
| Induction of CYP3As in HepG2 cells by several drugs. Association between induction of CYP3A4 and expression of glucocorticoid receptor | Q40658800 | ||
| Taurine modulates induction of cytochrome P450 3A4 mRNA by rifampicin in the HepG2 cell line | Q40690156 | ||
| Bcl-2 overexpression prevents calcium overload and subsequent apoptosis in dystrophic myotubes | Q41811040 | ||
| Involvement of TRPC in the abnormal calcium influx observed in dystrophic (mdx) mouse skeletal muscle fibers | Q41882302 | ||
| In situ measurements of calpain activity in isolated muscle fibres from normal and dystrophin-lacking mdx mice | Q42512800 | ||
| Essential role of TRPV2 ion channel in the sensitivity of dystrophic muscle to eccentric contractions | Q43258728 | ||
| The cytoprotective role of taurine in exercise-induced muscle injury | Q44055712 | ||
| Enhanced dystrophic progression in mdx mice by exercise and beneficial effects of taurine and insulin-like growth factor-1. | Q44255035 | ||
| The alteration of calcium homeostasis in adult dystrophic mdx muscle fibers is worsened by a chronic exercise in vivo | Q45098242 | ||
| Multiple pathological events in exercised dystrophic mdx mice are targeted by pentoxifylline: outcome of a large array of in vivo and ex vivo tests. | Q45129880 | ||
| A combined metabolomic and proteomic investigation of the effects of a failure to express dystrophin in the mouse heart | Q46043712 | ||
| Contrasting effects of steroids and angiotensin-converting-enzyme inhibitors in a mouse model of dystrophin-deficient cardiomyopathy | Q46113965 | ||
| Gentamicin treatment in exercised mdx mice: Identification of dystrophin-sensitive pathways and evaluation of efficacy in work-loaded dystrophic muscle | Q46434974 | ||
| Taurine depletion caused by knocking out the taurine transporter gene leads to cardiomyopathy with cardiac atrophy | Q46648922 | ||
| P433 | issue | 3 | |
| P921 | main subject | mdx mouse | Q24976962 |
| P304 | page(s) | 243-256 | |
| P577 | publication date | 2011-04-01 | |
| P1433 | published in | Neuropathology and Applied Neurobiology | Q7002494 |
| P1476 | title | Evaluation of potential synergistic action of a combined treatment with alpha-methyl-prednisolone and taurine on the mdx mouse model of Duchenne muscular dystrophy | |
| P478 | volume | 37 |
| Q57821110 | A long-term treatment with taurine prevents cardiac dysfunction in mdx mice |
| Q43845526 | Beneficial effects of high dose taurine treatment in juvenile dystrophic mdx mice are offset by growth restriction. |
| Q47349229 | Benefits of Prenatal Taurine Supplementation in Preventing the Onset of Acute Damage in the Mdx Mouse. |
| Q45871995 | ECM-Related Myopathies and Muscular Dystrophies: Pros and Cons of Protein Therapies |
| Q46463712 | Effects of prednisolone on the dystrophin-associated proteins in the blood-brain barrier and skeletal muscle of dystrophic mdx mice |
| Q38603674 | Enalapril treatment discloses an early role of angiotensin II in inflammation- and oxidative stress-related muscle damage in dystrophic mdx mice |
| Q36146630 | Increased taurine in pre-weaned juvenile mdx mice greatly reduces the acute onset of myofibre necrosis and dystropathology and prevents inflammation. |
| Q40219200 | Increasing taurine intake and taurine synthesis improves skeletal muscle function in the mdx mouse model for Duchenne muscular dystrophy. |
| Q37246026 | Levels of inflammation and oxidative stress, and a role for taurine in dystropathology of the Golden Retriever Muscular Dystrophy dog model for Duchenne Muscular Dystrophy |
| Q26772002 | Metabogenic and Nutriceutical Approaches to Address Energy Dysregulation and Skeletal Muscle Wasting in Duchenne Muscular Dystrophy |
| Q24568176 | Molecular and cell-based therapies for muscle degenerations: a road under construction |
| Q36925191 | Novel compounds for the treatment of Duchenne muscular dystrophy: emerging therapeutic agents |
| Q26849430 | Pre-clinical drug tests in the mdx mouse as a model of dystrophinopathies: an overview |
| Q96113189 | Safety issues and harmful pharmacological interactions of nutritional supplements in Duchenne muscular dystrophy: considerations for Standard of Care and emerging virus outbreaks |
| Q57064365 | Taurine and Methylprednisolone Administration at Close Proximity to the Onset of Muscle Degeneration Is Ineffective at Attenuating Force Loss in the Hind-Limb of 28 Days Mice |
| Q26799770 | Taurine: the appeal of a safe amino acid for skeletal muscle disorders |
| Q39016892 | The beneficial effects of taurine to counteract sarcopenia. |
| Q34077151 | The different impact of a high fat diet on dystrophic mdx and control C57Bl/10 mice |
| Q51625827 | The effect of taurine and β-alanine supplementation on taurine transporter protein and fatigue resistance in skeletal muscle from mdx mice. |
| Q38351283 | What has the mdx mouse model of Duchenne muscular dystrophy contributed to our understanding of this disease? |
Search more.